Evidence map›Paper›PMID 40442086›Full record

ArticleNature communications2025

High resolution clonal architecture of hypomutated Wilms tumours.

Henry Lee-Six, Taryn D Treger, Manas Dave, Tim Hh Coorens, Nathaniel D Anderson, Yvonne Tiersma, Sepide Derakhshan, Sanne de Haan, Marry M van den Heuvel-Eibrink, Yichen Wang and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Henry Lee-Six *Wellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0003-4831-8088
Taryn D Treger *Wellcome Sanger Institute, Hinxton, UK.
Manas DaveWellcome Sanger Institute, Hinxton, UK.
Tim Hh CoorensBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5826-3554
Nathaniel D AndersonWellcome Sanger Institute, Hinxton, UK.
Yvonne TiersmaPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sepide DerakhshanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sanne de HaanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7760-879X
Yichen WangWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0001-5122-7545
Anna WengerWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0001-6063-5401
Reem Al-SaadiUCL Great Ormond Street Institute of Child Health, London, UK.ORCID http://orcid.org/0000-0002-0816-5649
Alice LawfordGreat Ormond Street Hospital for Children, London, UK.
Aleksandra LetunovskaUCL Great Ormond Street Institute of Child Health, London, UK.
Jenny WegertTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Würzburg University & Comprehensive Cancer Center Mainfranken, Würzburg, Germany.ORCID http://orcid.org/0009-0009-4505-5519
Conor ParksWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0003-0240-0684
Guillaume MorcretteUCL Great Ormond Street Institute of Child Health, London, UK.
Manfred GesslerTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Würzburg University & Comprehensive Cancer Center Mainfranken, Würzburg, Germany.ORCID http://orcid.org/0000-0002-7915-6045
Gordan VujanicDepartment of Pathology, Sidra Medicine, Doha, Qatar.ORCID http://orcid.org/0000-0003-0726-6939
Tanzina ChowdhuryUCL Great Ormond Street Institute of Child Health, London, UK.
Maureen J O'SullivanDepartment of Pathology, Children's Health Ireland at Crumlin, Dublin, Ireland.
Ronald R de KrijgerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Michael R StrattonWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0001-6035-153X
Kathy Pritchard-JonesUCL Great Ormond Street Institute of Child Health, London, UK.ORCID http://orcid.org/0000-0002-2384-9475
J Ciaran HutchinsonGreat Ormond Street Hospital for Children, London, UK. Ciaran.hutchinson@gosh.nhs.uk.ORCID http://orcid.org/0000-0002-1708-2634
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. j.drost@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0002-2941-6179
Sam BehjatiWellcome Sanger Institute, Hinxton, UK. sb31@sanger.ac.uk.ORCID http://orcid.org/0000-0002-6600-7665

Funding

Wellcome TrustWellcome Trust 206194
6 · The paper itself

Abstract

A paradigm of childhood cancers is that they have a low mutation burden, with some ostensibly bearing fewer mutations than the normal tissues from which they derive. We set out to resolve this paradox by examining paediatric renal cancers with exceptionally few mutations using high resolution, high depth sequencing approaches. We find that apparent hypomutation is the result of unusual clonal architecture due to a normal tissue-like mode of tumour evolution, raising the possibility that the mutation burden of some cancers has been systematically misjudged.

Indexed as

Kidney NeoplasmsMutationWilms TumorChildChild, PreschoolClonal EvolutionFemaleHigh-Throughput Nucleotide SequencingHumansMale

Identifiers

PMID40442086
PMCPMC12122882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.